Rimonabant

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Dosage 4 Adverse-effects 5 Mechanism-of-action 6 More General Terms 7 Additional Terms 8 Internet Database 9 References

Introduction

• Tradename: Acomplia (withdrawn from European Market in 2009)

Indications

• obesity [2] (see RIO-North America study)
• smoking cessation
• hypercholesterolemia
• diabetes mellitus type 2 [5]

Dosage

• 5-20 mg QD

Adverse-effects

• depressed mood (< 4%) [7,9]
• nausea (<4%)
• anxiety (1%) [7,9]
• headache (<1%)
• seizures [6]

Mechanism-of-action

• selective cannabinoid receptor 1 ( CB1) antagonist
• diminishes appetite
• improves lipid profile
• improves glycemic control
• failed to reduce progression of coronary artery disease in patients with metabolic syndrome [8]

More General Terms

• anti-hyperlipidemic agent
• anorexiant (appetite suppressant)

Additional Terms

• cannabinoid receptor 1; CB1; CB-R; CANN6 (CNR1, CNR)
• RIO-North America study

Internet Database

PubChem: 104850
PubChem: 104849

References

1. Prescriber's Letter 11(11): 2004 Investigational Drug: Rimonabant (Acomplia) Detail-Document#: [1] (subscription needed) [2]
2. Journal Watch 25(12):98, 2005 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16;365(9468):1389-97. PMID: [3]
3. Despres JP, Golay A, Sjostrom L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121-34. PMID: [4]
4. Prescriber's Letter 13(3): 2006 Acomplia (Rimonabant) and OTC Orlistat for Weight Loss Detail-Document#: [5] (subscription needed) [6]
5. Sheen AJ et al, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 2006, 368:1660 PMID: [7]
6. Prescriber's Letter 14(7): 2007 (subscription needed) [8]
7. Christensen R et al, Efficacy and safety of the weight-loss drug remonant: A meta- analysis of randomised trials. Lancet 2007, 370:1706 PMID: [9]
8. Nissen SE et al, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRDIVARIUS randomized controlled trial. JAMA 2008, 299:1547 PMID: [10]
9. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007 Nov 17;370(9600):1706-13. Review. Erratum in: Lancet. 2008 Feb 16;371(9612):558. PMID: [11]

rimonabant (Acomplia, Zimulti)